SAI Parenteral’s (SPL), a diversified pharmaceutical formulation company, has acquired a 74.6% controlling stake in Noumed Pharmaceutical, an Adelaide-based pharmaceutical company, for an aggregate sum of ₹ 125 crore.
Noumed Pharmaceuticals, a company with AUD 60 million in revenue, is a supplier of private-label over-the-counter (OTC) products to pharmacy chains across Australia and New Zealand. The company is currently establishing a state-of-the-art manufacturing facility in Adelaide with an investment of AUD 53 million. The facility is expected to begin commercial operations by the fourth quarter of CY 2026. With a strong portfolio of over 451 product dossiers, Noumed offers substantial breadth across therapeutic categories.
Anil KK, Managing Director, SAI Parenteral’s, said, “This acquisition marks a pivotal and transformative milestone in our journey toward becoming a global, innovation-led formulations and CDMO platform. By combining Noumed’s R&D capabilities, distribution network, extensive dossier library, and upcoming manufacturing facility, along with SAI Parenterals’ strengths and capabilities in India, we are unlocking significant synergies across the value chain. This partnership enhances our entry into semi-regulated and regulated markets with a wider, more competitive product portfolio.”
“The acquisition also strengthens our ability to leverage Noumed’s established customer relationships and long-term supply contracts. Supported by Noumed’s regulatory capabilities, SAI Parenteral’s will further expand its presence across regulated markets, improving both revenue quality and visibility,” he adds.
Mark Thulborne, Managing Director, Noumed Pharmaceuticals, said, “We are excited to formalize this strategic partnership. Having worked with SAI Parenteral’s for a considerable time, we are confident that together we can accelerate our product pipeline, benefit from SAI’s manufacturing capabilities, and meet growing demand in the Australian, New Zealand, and global markets. This collaboration positions both companies to create substantial long-term value for all stakeholders.”
SAI Parenterals has also filed its IPO DRHP with SEBI on September 30, 2025, the offer, with a face value of ₹5 per equity share, comprises a fresh issue of up to ₹285 crore and an offer for sale of up to 3,500,000 equity shares by existing shareholders.
SAI Parenteral’s is backed by marquee investors, including Samarsh Capital, Vyom Partners, Blue Lotus Capital and Gruhas.
